Recent News

• 02.09.2026 - Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
• 02.05.2026 - Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 01.07.2026 - Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
• 10.28.2025 - Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
• 10.20.2025 - Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

Recent Filings

• 02.10.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.04.2025 - 8-K Current report
• 11.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 4/A Statement of changes in beneficial ownership of securities
• 11.06.2025 - 4/A Statement of changes in beneficial ownership of securities